• Gaurav Batra, Deepika Rathna Murugesan, Sreevatsan Raghavan, Souvick Chattopadhyay, Farha Mehdi, AyushiCentre for Maternal and Child Health, Faridabad, Haryana, India., Mudita Gosain, Savita Singh, Soon Jyoti Das, Suprit Deshpande, Sudipta Sonar, Kamini Jakhar, Jayanta Bhattacharya, Shailendra Mani, Anil Kumar Pandey, SankalpDepartment of Physiology, ESIC Medical College & Hospital, Faridabad, Haryana, India., Shweta Goswami, Asim Das, Tanima Dwivedi, Nandini Sharma, Suresh Kumar, Pragya Sharma, Seema Kapoor, Pallavi Kshetrapa, Nitya Wadhwa, Ramachandran Thiruvengadam, Rakesh Kumar, Ritu Gupta, GargPramod KumarPKTranslational Health Science and Technology Institute, Faridabad, Haryana, India., and Shinjini Bhatnagar.
• Centre for Bio Design and Diagnostics, Faridabad, Haryana, India.
• Indian J Med Res. 2023 Jun 1; 157 (6): 509518509-518.

Background & ObjectivesVaccination and natural infection can both augment the immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but how omicron infection has affected the vaccine-induced and hybrid immunity is not well studied in Indian population. The present study was aimed to assess the durability and change in responses of humoral immunity with age, prior natural infection, vaccine type and duration with a minimum gap of six months post-two doses with either ChAdOx1 nCov-19 or BBV152 prior- and post-emergence of the omicron variant.MethodsA total of 1300 participants were included in this observational study between November 2021 and May 2022. Participants had completed at least six months after vaccination (2 doses) with either ChAdOx1 nCoV-19 or an inactivated whole virus vaccine BBV152. They were grouped according to their age (≤ or ≥60 yr) and prior exposure of SARS-CoV-2 infection. Five hundred and sixteen of these participants were followed up after emergence of the Omicron variant. The main outcome was durability and augmentation of the humoral immune response as determined by anti-receptor-binding domain (RBD) immunoglobulin G (IgG) concentrations, anti-nucleocapsid antibodies and anti-omicron RBD antibodies. Live virus neutralization assay was conducted for neutralizing antibodies against four variants - ancestral, delta and omicron and omicron sublineage BA.5.ResultsBefore the omicron surge, serum anti-RBD IgG antibodies were detected in 87 per cent participants after a median gap of eight months from the second vaccine dose, with a median titre of 114 [interquartile range (IQR) 32, 302] BAU/ml. The levels increased to 594 (252, 1230) BAU/ml post-omicron surge (P<0.001) with 97 per cent participants having detectable antibodies, although only 40 had symptomatic infection during the omicron surge irrespective of vaccine type and previous history of infection. Those with prior natural infection and vaccination had higher anti-RBD IgG titre at baseline, which increased further [352 (IQR 131, 869) to 816 (IQR 383, 2001) BAU/ml] (P<0.001). The antibody levels remained elevated after a mean time gap of 10 months, although there was a decline of 41 per cent. The geometric mean titre was 452.54, 172.80, 83.1 and 76.99 against the ancestral, delta, omicron and omicron BA.5 variants in the live virus neutralization assay.Interpretation & ConclusionsAnti-RBD IgG antibodies were detected in 85 per cent of participants after a median gap of eight months following the second vaccine dose. Omicron infection probably resulted in a substantial proportion of asymptomatic infection in the first four months in our study population and boosted the vaccine-induced humoral immune response, which declined but still remained durable over 10 months.

21 keywords...

hide…